Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mucosis Secures Agentschap Financing For FluGEM Program
According to Mucosis, the loan will be redeemed only if the FluGEM clinical development program is concluded successfully. Mucosis develops vaccines on the basis of its Mimopath technology,
According to Mucosis, the loan will be redeemed only if the FluGEM clinical development program is concluded successfully. Mucosis develops vaccines on the basis of its Mimopath technology,
The Ubichem isotope synthesis group has experience in the synthesis of labelled compounds for use by pharmaceutical and biotech companies in pharmacokinetic and metabolic studies, and will now
The public-private partnership aims at taking advantage of the joint know-how in research and development of Sanofi-aventis and Charite to develop approaches faster and make them accessible to
EpiCept said that Ceplene is approved in the EU for remission maintenance and prevention of relapse in adults with acute myeloid leukemia (AML) in first complete remission. EMA
The Phase 1/2 study is recruiting patients with advanced or treatment-refractory HCC. Patients in this trial are tested at entry for infection with hepatitis C virus (HCV). Although
Recently, Scottish Medicines Consortium (SMC) has accepted the use of Novartis’ omalizumab for children in Scotland aged 6 to 11 years with severe, persistent allergic asthma who are
The acquisition is expected to bolster Centocor Ortho Biotech’s pulmonary portfolio and capabilities, allowing it to gain access to RespiVert’s portfolio of early-stage inhaled treatments for serious lung
The licenses granted to OMJ include worldwide licenses to Orexo’s ongoing OX-CLI and OX-ESI programs focusing on discovering and developing new small-molecule treatments for asthma, chronic obstructive pulmonary
Angel Biotechnology said that the contract, for process development and GMP manufacture of specific antibodies, is valued at circa GBP1.3m. Work on the project is expected to start
Celladon said that the new data showed improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy. Reportedly,